Equity Research Coverage Reports

Creso Pharma Limited (ASX: CPH) - First Company to Import Medicinal Cannabis Product into Australia
Thursday, March 1, 2018
While the company has taken significant steps to put themselves in a position to be a significant player in the emerging hemp extract and medicinal cannabis market, the company is in the early stages of growth and is operating in a highly competitive market. With the company undergoing product development and currently generating low levels of revenue, an investment in the company remains speculative
Download Report
Chatham Rock Phosphate (TSXV:NZP, NZAX:CRP, FSE:3GRE) - Low Capex, High Quality Phosphate
Tuesday, October 17, 2017
We have completed a risked DCF valuation for CRP, with the tabular form presented in our report. This is a base case valuation, with significant upside on de-risking, particularly with grant of the Marine Consents. The per share valuation is based on the current share structure diluted for raisings of US$14.14 million as flagged by the Company.
Download Report
Sienna Cancer Diagnostics Limited (ASX: SDX) - IVD Test for Bladder Cancer - Distribution Agreements in the US & Europe
Monday, October 9, 2017
We have determined a base case valuation for SDX of $0.31 per share. The valuation incorporates a number of assumptions regarding the sales of the IVD product for the detection of bladder cancer in the US and Europe. The product has been de-risked to a large extent given the company has obtained an IVD classification in the US, Europe and Australia.
Download Report
Allegiance Coal (ASX:AHQ) - Low Cost Metallurgical Coal - British Columbia, Canada - Expect Production late 2019
Friday, September 22, 2017
We have a base case valuation of A$0.37/share for Telkwa - this is based on the small scale operation, and we see significant upside to $0.82/share in this with the ultimate, full-scale operation, and also upside with success on permitting and execution. We note that these figures are based on unfunded and pre-tax Telkwa Project modelling
Download Report
Race Oncology Limited (ASX: RAC) - Big Strides in the Re-Development of Bisantrene - Target Available for use in Europe & South Korea in 2 years
Friday, September 22, 2017
Our base case valuation for RAC remains at $0.44 per share. Our valuation is based on a fully diluted basis. The company is expected to generate revenue over the shortterm through the sale of Bisantrene under the NPP throughout the four above mentioned countries.RAC intends to make Bisantrene available for use in Europe and South Korea. The company is also seeking to gain approval by the FDA for its drug via the 505(b)(2) route.
Download Report